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Abstract
Background:  In an elderly, community based population we aimed at investigating
antihypertensive and lipid lowering medication use in relation to own and familiar cardiovascular
morbidity and diabetes mellitus, as well as to lifestyle factors and general health. We also examined
levels of blood pressure in untreated and treated residents, to investigate factors correlating with
blood pressure control.
Methods: A health survey carried out in 1997-9 in the county of Hordaland, Norway included a
self-administered questionnaire mailed to 4 338 persons born in 1925-7. Drug use the day prior to
filling in the questionnaire was reported. A health check-up was carried out, where their systolic
and diastolic blood pressure (SBP and DBP), body mass index (BMI), and serum-cholesterol level
were recorded.
Results: One third of respondents used one or more antihypertensive drugs, while 13% of men
and women were treated with a statin. Diabetes mellitus, own or relatives'cardiovascular disease,
having quit smoking, physical inactivity, and overweight correlated with antihypertensive treatment.
Mean blood pressure was lower in respondents not on treatment. Among those on treatment, 38%
of men and 29% of women had reached a target BP-level of lower than 140/90 mm Hg. Own
cardiovascular disease and a low BMI correlated with good BP-control.
Conclusion: One third of 70–74 year old individuals living in the community used one or more
antihypertensive drugs. Only around one third of those treated had reached a target BP-level of
less than 140/90 mm Hg. Own cardiovascular disease and a low BMI correlated with good BP-
control.
Background
During the past decades, an increasing body of evidence
has emerged on the importance of blood pressure as a risk
factor for cardiovascular disease also in elderly people.
Current European and US guidelines reinforce that doc-
tors should not focus solely on hypertension, but include
blood lipids and lifestyle factors in a multi-factorial risk
assessment [1,2]. Since the first guideline on the manage-
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ment of hypertension were issued by the WHO in 1962
[3], subsequent versions have emerged at regular intervals.
In general, the newer the guidelines, the lower the blood
pressure (BP) cut-off points for intervention, and a corre-
sponding trend also applies to the guidelines for blood
lipids [4].
Most pharmacological interventions for modifying cardi-
ovascular risk factors take place in general practice. How-
ever, two conflicting concerns have emerged. The first,
often expressed by general practitioners (GPs), is that the
cut-off points are now so low that only a minority of eld-
erly persons will be regarded as "normal" or "healthy"
without a need for drug treatment [5]. The second concern
is that GPs' present treatment practice is insufficient,
because hypertension and hyperlipidemia too often go
unrecognized or are not treated aggressively enough [6,7].
The aim of this study was first, to analyze the level of eld-
erly peoples' use of antihypertensive and lipid lowering
drugs in relation to own and relatives' cardiovascular dis-
ease and diabetes mellitus, own lifestyle factors, BMI and
general health status. The second aim was to investigate
present BP in elderly people with or without treatment,
and factors correlating with good BP-control.
Methods
The Hordaland Health Study (HUSK)
In 1997-9 a population based health survey was carried
out in Hordaland County in western Norway (with capital
city Bergen): The Hordaland Health Survey (HUSK) [8]. In
total, 44 342 persons were invited, among whom 4 338
were 70–74 year old (born between 1925 and 1927) and
living in Bergen and three nearby communities. The sur-
vey was carried out by the National Health Screening Serv-
ice, Oslo (now The Norwegian Institute of Public Health)
in cooperation with the University of Bergen.
Questionnaire and measurements
A questionnaire was mailed to the invited persons, along
with an invitation to a health check-up. The questionnaire
included the following questions regarding drug con-
sumption: Did you take any drugs yesterday? (yes/no). If
yes: report the name of the drug, the reason for taking it,
and whether you usually take this drug every day (yes/no).
The questionnaire provided space for reporting up to nine
different drugs, and participants were asked to continue
on a separate sheet if needed. The questionnaire also
addressed physical exercise, smoking, alcohol use, general
health, and depressive symptoms, duration of formal edu-
cation, previous or present diabetes mellitus and cardio-
and cerebrovascular disease (including family history).
Some variables were dichotomized during data analysis
(see Table 1).
The completed questionnaires were gathered at the
screening station. Here, systolic (SBP) and diastolic blood
pressure (DBP), (average of the last two out of three
recordings), as well as height and weight for calculating
body mass index (BMI) were recorded. Blood samples
were drawn for analyzing (among others) serum choles-
terol.
The drugs reported to be used were subsequently coded
according to the 1996- version of the Anatomical Thera-
peutic Chemical (ATC) classification system [9]. The ATC-
groups included in this analysis were: C02 Anti-adrenergic
agents, C03 Diuretics, C07 Beta blocking agents, C08 Cal-
cium channel blockers, C09 Agents affecting the renin-
angiotensin system, and C10 Lipid lowering agents.
Reported reasons for drug use were coded based on a
modified list of diagnoses according to the International
Classification for Primary Care (ICPC) [10].
Ethics and statistics
The study was approved by the Regional Committee for
Medical Research Ethics and the Norwegian Data Inspec-
torate.
Statistical analyses were performed using SPSS version 11.
Bivariate comparisons were performed using chi-square
test or independent samples t-test. Level of statistical sig-
nificance was set at 5% (p < 0.05).
Results
Out of the 4 438 elderly persons invited, 3 341 (77%)
responded by filling in the questionnaire and attending
the health check-up. They comprise the material for this
study. 1 301 persons (39% of all; 585 men, 716 women)
reported daily use of antihypertensives or statins. Mean
number of these drugs per user was 1.62. Among the 445
statin users, 286 (64%) were also on antihypertensive
treatment. Out of the 518 men (35%) and 626 women
(33%) using antihypertensives, 51% reported "elevated
blood pressure" as indication for use, 20% reported "car-
diac problems," and 29% reported some other indications
or gave no explicit reason for use.
The distribution of the antihypertensives according to
ATC-groups was: anti-adrenergic agents: 95, diuretics:
233, beta blocking agents: 515, calcium channel blockers:
390, and agents affecting the renin-angiotensin system:
439.
Among persons who had suffered myocardial infarction,
70% of men and 82% of women were on antihypertensive
drug treatment. For cerebral stroke, corresponding figures
were 63% (men) and 47% (women), and for angina pec-
toris 67% (men) and 74% (women). Among men withBMC Geriatrics 2006, 6:16 http://www.biomedcentral.com/1471-2318/6/16
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diabetes mellitus, 58% were on antihypertensive treat-
ment while this applied to 57% in women.
Cardiovascular morbidity in close relatives (parents,
brothers or sisters) was strongly correlated with antihyper-
tensive drug use (Table 2). Among persons with a positive
family history of myocardial infarction, 42% of men and
38% of women were on treatment. For those with a family
history of early (< 60 years of age) myocardial infarction,
the numbers were 43% and 39%, for early (< 70 y) apo-
plexia 43% and 41%, respectively. Daily smoking was
negatively correlated to antihypertensive treatment, as
was doing physical exercise or having a BMI < 27 kg/m2.
Formal education < 12 years, feeling depressed (women),
and a less than good self-reported health all correlated
positively to treatment.
In the population on antihypertensive treatment, 23%
reported angina pectoris, 21% myocardial infarction,
11% diabetes mellitus, and 7% apoplexia.
Statins were used by 195 men (13%) and 244 women
(13%) (Table 3). Own and familiar cardiovascular dis-
ease, as well as diabetes mellitus correlated with statin use
(bivariate analyses). Among those not using a statin, 84%
of men and 92% of women had total cholesterol levels >
5 mmol/l, while corresponding figures for statin users
were 56% of men and 80% of women.
SBP was significantly higher in persons on antihyperten-
sive treatment compared to persons not on BP-lowering
medications (Table 4). DBP was higher for women in the
treatment group, but not for men. Among those treated,
38% of men and 29% of women had reached a target level
of BP < 140/90 (Table 4). Previous cardiovascular events,
not being overweight, using a statin, and reporting a good
general health (in women only) correlated with a success-
ful BP-control in those on treatment (Table 5).
Discussion
The high response rate (77%) contributes to strengthen
the external validity of the findings. Furthermore, we con-
sider data quality to be good, as drug names generally
were correctly written and only few questionnaires had to
be rejected because of inconsistencies.
However, some limitations have to be considered. First,
people with a poor health, low socioeconomic status and
an unhealthy lifestyle are generally known to be over-rep-
resented among non-respondents in health surveys [11],
and unpublished HUSK-data reveal that in the elderly
population, non-participants had lower education and
income. We therefore find it likely that the 23% who did
not participate in this survey use more drugs than the
respondents. Second, the validity of elderly persons' self-
reported drug use and reasons for use may be questioned.
However, asking which drugs were taken the previous day
Table 1: Questions on lifestyle and health status
Physical activity
Which level of physical activity have you had during the last year?
• Easy exercise:none, less than 1 hour/week, 1–2 hours/week, 3 hours or more/week
• Hard exercise:none, less than 1 hour/week, 1–2 hour/week, 3 hours or more/week
Use of alcohol
• Are you totally abstinent from alcohol? Yes/no
• How many times a month do you usually drink alcohol? Number of times:
• How many glasses of beer, wine or spirits do you usually drink during a two-week period? Number of glasses:
Smoking
• Do you smoke cigarettes daily? Yes/no
• If you used to be a daily smoker, since when did you quit? Number of years:
• If you are or were a daily smoker, how many cigarettes do or did you usually smoke during a day? Number of cigarettes:
• For how many years have you been a daily smoker? Number of years:
General health
• How is your present general state of health? Bad/not quite good/good/very good*
Depressed mood
Have you felt down/depressed during the last two weeks? Yes/a little/
• considerably/very much**
* Less than good general health: bad or not so good
** Depressed mood: yes or a littleBMC Geriatrics 2006, 6:16 http://www.biomedcentral.com/1471-2318/6/16
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(i.e. point prevalence) probably minimized recall bias
[12]. Asking which drugs were actually taken also
bypassed the problem of non-compliance, as we know
that around 25% of prescribed drugs may not be used
[13,14]. This also applies to BP- and lipid lowering drugs
[15], which suggests that some of the non-users here prob-
ably had been prescribed some antihypertensive or lipid
lowering drug.
We chose to include all use of drugs with ATC-codes C02,
C03, C07, C08, or C09 in the analyses and to label them
as "antihypertensive drugs", although some patients obvi-
ously used e.g. diuretics or beta-blockers for other cardio-
vascular reasons. Out of all users of the listed ATC-drugs,
as many as 29% reported no explicit diagnostic reason for
taking them, and some gave very unspecific or obviously
wrong indications. In addition, as many as 63 persons
reported "elevated BP" for use of drugs not relevant for
antihypertensive treatment. Our figures here correspond
well with results in a comprehensive British interview
study among people aged 65 +, where 24% did not know
the reason for taking their medications [13]. We therefore
focused on our reliable registration of drug names, with-
out paying attention to self-reported indications for use,
which may represent a further limitation of this study.
In Western countries, elderly people are the major drug
consumers and the average number of daily drugs used
Table 3: The Hordaland Health Study (HUSK). Own and familiar cardiovascular morbidity in 3 341 elderly persons (70 – 74 years old), 
using and not using lipid lowering drugs.
Males (n = 1473) Females (n = 1868)
No drugs (n = 1278 86.8%) Drugs (n = 195 13.2%) No drugs (n = 1642 87.1%) Drugs (n = 244 13.1%)
Cardiac infarction 108 (8.4) 104 (53.3)** 52 (3.2) 61 (25.0)**
Angina pectoris 103 (8.1) 103 (52.8)** 104 (6.3) 69 (28.3)**
Apoplexia 72 (5.6) 15 (7.7) 46 (2.8) 14 (5.7)*
Diabetes mellitus 81 (6.3) 24 (12.3)** 92 (5.6) 25 (10.2)**
Family history of coronary disease 480 (37.6) 108 (55.4)** 749 (45.6) 163 (66.8)**
Family history of cardiac infarction < 60 y 179 (14.0) 46 (23.6) 264 (16.1) 72 (29.5)**
Family history of apoplexia < 70 y 149 (11.7) 27 (13.8)** 249 (15.2) 42 (17.2)
Proportions, given in numbers and percentages, are compared using chi square tests.
*Significant difference between samples with versus without drugs, p < 0.05
**Significant difference between samples with versus without drugs, p < 0.01
Table 2: The Hordaland Health Study (HUSK). Own and familiar cardiovascular morbidity, lifestyle factors, and health status in 3 341 
elderly persons (70 – 74 years old), using and not using antihypertensive drugs.
Males (n = 1473) Females (n = 1868)
No drugs (n = 955 64.8%) Drugs (n = 518 35.2%) No drugs (n = 1260 66.8%) Drugs (n = 626 33.2%)
Myocardial infarction 63 (6.6) 149 (28.8)** 20 (1.6) 93 (14.9)**
Angina pectoris 68 (7.1) 138 (26.6)** 45 (3.6) 128 (20.4)**
Apoplexia 32 (3.4) 55 (10.6)** 32 (2.5) 28 (4.5)*
Diabetes mellitus 40 (4.2) 56 (10.8)** 52 (4.1) 65 (10.4)**
Family history of coronary disease 364 (38.1) 224 (43.2)** 566 (44.9) 346 (55.3)**
Family history of myocardial infarction < 60 y 129 (13.5) 96 (18.5)* 206 (16.3) 130 (20.8)*
Family history of apoplexia < 70 y 100 (10.5) 76 (14.7)* 173 (13.7) 118 (18.8)*
Daily smoking 158 (16.5) 57 (11.0)** 210 (16.7) 57 (9.1)**
Quit smoking 543 (56.9) 351 (67.8)** 283 (22.5) 170 (27.2)*
Alcohol > 14 times/month 79 (9.7) 48 (10.7) 45 (4.5) 13 (2.7)
No physical exercise 108 (12.0) 72 (14.5) 170 (15.3) 125 (22.1)**
Hard physical exercise 337 (38.8) 134 (28.5)** 213 (20.5) 88 (16.6)
BMI => 27 kg/m2 289 (30.3) 210 (40.5)** 431 (34.7) 314 (50.2)**
Education < 12 y 297 (57.4) 181 (65.1)* 573 (79.9) 304 (86.4)*
Depressed mood 29 (3.5) 11 (2.5) 37 (3.7) 32 (6.8)**
Less than good general health 212 (22.6) 180 (35.7)** 389 (31.9) 285 (46.5)**
Proportions, given in numbers and percentages, are compared using chi square tests.
*Significant difference between samples with versus without drugs (chi square test), p < 0.05.
**Significant difference between samples with versus without drugs (chi square t-test), p < 0.01BMC Geriatrics 2006, 6:16 http://www.biomedcentral.com/1471-2318/6/16
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per person is increasing [13,16-19]. In another paper from
this survey, we have reported that two thirds of men and
three out of four women took at least one ATC-drug, with
hypertension and other cardiovascular problems being by
far the most common reasons for drug use [20]. In the eld-
erly, cardiovascular drugs are generally reported to be the
most commonly used drugs, though exceptions exist
[13,16,18,21].
There were no significant differences between the two gen-
ders' total use of BP- and cholesterol lowering drugs,
whereas a low formal education correlated with more use.
This is also reported by others [16,22] and probably mir-
rors the well-known inverse relationship between social
class and (risk of) cardiovascular disease [23]. In this sur-
vey, feeling depressed correlated strongly with total drug
use [20], but logically this correlation was less pro-
nounced for cardiovascular drugs, as compared to e.g. psy-
chotropic drugs. Reporting a depressed mood only
correlated positively with the use of antihypertensive or
lipid lowering drugs in women.
Not surprisingly, performing no regular exercise or report-
ing a less than good general health were also associated
with more use of BP- and cholesterol lowering drugs, cor-
responding to the results of others [24]. It may be surpris-
ing that being a non-smoker or having quit smoking both
correlated positively with more drug use. That former
smokers were those most likely to be on some medica-
tion, corresponds to what has been found in other studies
[24,25]. One explanation may be that people who fall ill
and are put on regular medication, tend to quit smoking,
while smokers who remain healthy, more likely continue
smoking. Other explanations are that a significant share of
Table 5: The Hordaland Health Study (HUSK). Predictors for successful blood pressure-control in 1144 elderly persons (70–74 years 
old) on antihypertensive treatment.
Males (n = 518) Females (n = 626)
BP < 140/90 n = 195 SBP ≥ 140 or DBP ≥ 90 n = 323 BP=<140/90 n = 183 SBP ≥ 140 or DBP ≥ 90 n = 443
Cardiovascular disease 130 (66.7) 131 (40.6)** 73 (39.9) 118 (26.6)**
Diabetes mellitus 23 (12.3) 33 (10.4) 15 (8.5) 50 (11.5)
Family history of early CVD 50 (25.6) 99 (30.7) 62 (33.9) 150 (33.9)
Daily smoking 23 (11.9) 34 (10.8) 16 (9.1) 41 (10.0)
Quit smoking 133 (67.5) 218 (68.2) 50 (27.3) 120 (27.1)
Alcohol > 14 times/month 16 (9.4) 32 (11.5) 2 (1.4) 11 (3.2)
No physical exercise 29 (15.7) 43 (13.9) 39 (23.9) 86 (21.4)
Hard physical exercise 44 (25.0) 90 (30.6) 24 (15.4) 64 (17.3)
BMI => 27 kg/m2 63 (32.3) 147 (45.5)** 80 (43.7) 234 (52.8)*
Education < 12 years 68 (65.4) 113 (64.9) 81 (86.2) 223 (86.4)
Depressed mood 5 (3.1) 6 (2.1) 11 (8.1) 21 (6.3)
Less than good general health 76 (40.2) 104 (33.0) 94 (53.1) 191 (43.8)*
Statin treatment 60 (30.8) 68 (21.1)* 58 (31.7) 96 (21.7)*
Proportions, given in numbers and percentages, are compared using chi-square tests.
*p < 0.05
**p < 0.01
Table 4: The Hordaland Health Study (HUSK). Blood pressure (BP) in 3 341 elderly persons (70 – 74 years old), using and not using 
antihypertensive drugs.
Males (n = 1473) Females (n = 1868)
No drugs (n = 955) Drugs (n = 518) No drugs (n = 1260) Drugs (n = 626)
Systolic BP (mm Hg) 144.5 (18.7) 91/210 147.5* (21.5) 88/223 145.6 (22.0) 98/229 153.4* (21.6) 84/220
Diastolic BP (mm Hg) 80.0 (10.7) 48/120 80.1 (12.1) 46/116 75.0 (12.6) 44/131 77.8* (12.1) 40/123
BP < 140/90 mmHg (%) 42.2 37.6 44.4 29.2**
Figures are given as means with standard deviation (SD) and range (minimum/maximum).
*Significant difference between samples with versus without drugs, independent samples t-test p < 0.01.
** Significant difference between sample with versus without drugs, chi square test p < 0.01BMC Geriatrics 2006, 6:16 http://www.biomedcentral.com/1471-2318/6/16
Page 6 of 7
(page number not for citation purposes)
the heavy smokers probably has died before reaching an
age of 70–74 years [26], and that smokers may be over-
represented among the non-responders.
Use of alcohol every second day or more often did not cor-
relate with antihypertensive treatment. Underreporting of
actual drinking may have occurred, but contrary to smok-
ing, regular, moderate alcohol consumption seems to be
associated with less cardiovascular morbidity and mortal-
ity [27]. In an American study, no significant relationship
was found between current use of alcohol and medica-
tions among persons 65 and over [24].
In the medical community, a tension exists between
avoiding excessive use of medications for the elderly and
to provide access to therapies that have beneficial effects
on mortality, morbidity, functioning and quality of life
[28,29]. This dilemma is especially pronounced for cardi-
ovascular drugs, since they are so commonly used for pri-
mary and secondary risk prevention. Using drugs for
secondary prevention in cardiovascular disease is effective
in individuals 65 years and older, and prescription on this
indication is recommended for all without contraindica-
tions [30]. However, drug treatment as primary preven-
tion is becoming ever more present, even in older age
groups, reflecting the new guidelines [1,2]. Implementing
the 2003 European guidelines on CVD prevention [1] on
a population from another Norwegian county, Getz et al
estimated that around 90% of adults 50 years or older in
fact were in need of some interventions due to their unfa-
vorable cholesterol and/or BP values [5]. Because so few
are regarded healthy according to these guidelines, the
authors expressed serious concerns regarding medicaliza-
tion, resource allocation, and sustainability within the
healthcare system.
On the other hand: Our finding that less than 40% of
those already on BP-lowering drugs had actually reached
the recommended BP levels, indicates substantial poten-
tials for improving their treatment. This finding, which is
in line with others, indicate that a large proportion of
treated patients still have inadequate control of their BP.
In particular, being overweight correlated with a poor BP-
control [7,31]. Corresponding to our findings, a recent
Norwegian study showed that nearly two thirds of 75 year
olds on antihypertensive treatment still had not reached a
target BP-level [7].
Conclusion
Around one third of 70–74 year old men and women liv-
ing in the community used one or more antihypertensive
drugs, and 13% of men and women used a statin. Diabe-
tes mellitus, own or relatives' cardiovascular disease,
being physically inactive, overweight, and being an ex-
smoker correlated with antihypertensive treatment.
Among those on drug treatment, less than 40% of men
and 30% of women had reached the recommended target
values for blood pressure (below 140/90 mmHg), and
being overweight correlated with poor BP control.
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